6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Impact of Inflammatory Bowel Disease on Pubertal Growth

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Puberty is thought to be commonly affected in adolescents with inflammatory bowel disease (IBD). Aims: To determine the impact of Crohn’s disease (CD) and ulcerative colitis (UC) on the pubertal growth spurt. Methods: Retrospective study of 30 boys with CD (CD-M), 11 girls with CD (CD-F), 14 boys with UC (UC-M) and 12 girls with UC (UC-F). Pubertal growth was assessed by calculating peak height velocity SDS (PHV SDS), height SDS at diagnosis (Ht<sub>Diag</sub>) and height SDS at PHV (Ht<sub>PHV</sub>) and age at PHV (Age<sub>PHV</sub>). Systemic markers of disease activity were also collected. Results: Altered parameters of pubertal growth were observed in the CD groups compared to the normal population: in the CD-M group, median Ht<sub>Diag</sub> was –0.56 (p = 0.001) and median Age<sub>PHV</sub> was 14.45 years (p = 0.004), and in the CD-F group, median Ht<sub>Diag</sub> was –1.14 (p = 0.007) and Ht<sub>PHV</sub> was –0.79 (p = 0.039). Individually, 8/30 CD-M cases had one or more parameter affected: 2 boys had Ht<sub>Diag </sub><–2, 3 boys had Ht<sub>PHV</sub> <–2, 2 boys had an Age<sub>PHV</sub> >2 years above population mean, and 2 boys had a PHV SDS <–2. In the whole group, Age<sub>PHV</sub> showed an association with erythrocyte sedimentation rate (r = 0.4; p = 0.005) and an inverse association with BMI (r = 0.4; p = 0.001). Conclusion: Disorders of pubertal growth are more likely to occur in CD and, particularly, in boys.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: not found
          • Article: not found

          Standards for children's height at ages 2-9 years allowing for heights of parents.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Age at Puberty and the Emerging Obesity Epidemic

            Background Recent studies have shown that puberty starts at younger ages than previously. It has been hypothesized that the increasing prevalence of childhood obesity is contributing to this trend. The purpose of this study was to analyze the association between prepubertal body mass index (BMI) and pubertal timing, as assessed by age at onset of pubertal growth spurt (OGS) and at peak height velocity (PHV), and the secular trend of pubertal timing given the prepubertal BMI. Methodology/Principal Findings Annual measurements of height and weight were available in all children born from 1930 to 1969 who attended primary school in the Copenhagen municipality; 156,835 children fulfilled the criteria for determining age at OGS and PHV. The effect of prepubertal BMI at age seven on these markers of pubertal development within and between birth cohorts was analyzed. BMI at seven years was significantly inversely associated with age at OGS and PHV. Dividing the children into five levels of prepubertal BMI, we found a similar secular trend toward earlier maturation in all BMI groups. Conclusion/Significance The heavier both boys and girls were at age seven, the earlier they entered puberty. Irrespective of level of BMI at age seven, there was a downward trend in the age at attaining puberty in both boys and girls, which suggests that the obesity epidemic is not solely responsible for the trend.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis-The Porto Criteria

              &NA; (2005)
                Bookmark

                Author and article information

                Journal
                HRP
                Horm Res Paediatr
                10.1159/issn.1663-2818
                Hormone Research in Paediatrics
                S. Karger AG
                1663-2818
                1663-2826
                2011
                November 2011
                18 October 2011
                : 76
                : 5
                : 293-299
                Affiliations
                aDevelopmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Sick Children, and bDepartment of Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK
                Author notes
                *Prof. S. Faisal Ahmed, MD, FRCPCH, Department of Child Health, University of Glasgow, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ (UK), Tel. +44 141 201 0571, E-Mail faisal.ahmed@glasgow.ac.uk
                Article
                329991 Horm Res Paediatr 2011;76:293–299
                10.1159/000329991
                22024935
                94dc1553-58ea-4703-a5b8-e5b7376da42e
                © 2011 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 08 April 2011
                : 03 June 2011
                Page count
                Figures: 4, Tables: 1, Pages: 7
                Categories
                Original Paper

                Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
                Inflammation,Growth,Hypogonadism,Chronic disease

                Comments

                Comment on this article